Pieter Annaert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8868688/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Systemic availability and metabolism of colonicâ€derived shortâ€chain fatty acids in healthy subjects: a stable isotope study. Journal of Physiology, 2017, 595, 541-555.	1.3	254
2	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2â^'infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26955-26965.	3.3	240
3	Ordered Mesoporous Silica Material SBA-15: A Broad-Spectrum Formulation Platform for Poorly Soluble Drugs. Journal of Pharmaceutical Sciences, 2009, 98, 2648-2658.	1.6	237
4	Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 223-230.	2.0	221
5	Strategies for Absorption Screening in Drug Discovery and Development. Current Topics in Medicinal Chemistry, 2001, 1, 367-383.	1.0	207
6	Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. European Journal of Pharmaceutical Sciences, 2010, 41, 623-630.	1.9	180
7	A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption. European Journal of Pharmaceutical Sciences, 2014, 57, 322-332.	1.9	159
8	The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats. American Journal of Pathology, 2015, 185, 409-419.	1.9	156
9	Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica, 2010, 40, 163-176.	0.5	148
10	Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice. Antimicrobial Agents and Chemotherapy, 1998, 42, 1568-1573.	1.4	135
11	Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2009, 63, 767-770.	1.3	125
12	Excipient-Mediated Supersaturation Stabilization in Human Intestinal Fluids. Molecular Pharmaceutics, 2011, 8, 564-570.	2.3	119
13	Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metabolism Reviews, 2016, 48, 88-112.	1.5	119
14	In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3. Drug Metabolism and Disposition, 2010, 38, 25-31.	1.7	115
15	Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole. Clinical Pharmacokinetics, 2011, 50, 725-734.	1.6	114
16	Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 354-365.	2.0	111
17	Structure-Based Identification of OATP1B1/3 Inhibitors. Molecular Pharmacology, 2013, 83, 1257-1267.	1.0	110
18	Sandwich-cultured hepatocytes: utility for <i>in vitro</i> exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 589-616.	1.5	110

#	Article	IF	CITATIONS
19	Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs. Pharmaceutical Research, 2009, 26, 1456-1466.	1.7	109
20	Drug precipitation–permeation interplay: Supersaturation in an absorptive environment. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 424-428.	2.0	107
21	Albumin is the main plasma binding protein for indoxyl sulfate and <i>p</i> resyl sulfate. Biopharmaceutics and Drug Disposition, 2013, 34, 165-175.	1.1	104
22	High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. American Journal of Transplantation, 2016, 16, 2954-2963.	2.6	102
23	Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids. European Journal of Pharmaceutical Sciences, 2011, 43, 260-269.	1.9	97
24	Drug Supersaturation in Simulated Human Intestinal Fluids Representing Different Nutritional States. Journal of Pharmaceutical Sciences, 2010, 99, 4525-4534.	1.6	88
25	Food-dependent disintegration of immediate release fosamprenavir tablets: In vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 313-319.	2.0	84
26	Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes. Drug Metabolism and Disposition, 2008, 36, 1119-1125.	1.7	82
27	Intramuscular Administration of Paliperidone Palmitate Extended-Release Injectable Microsuspension Induces a Subclinical Inflammatory Reaction Modulating the Pharmacokinetics in Rats. Journal of Pharmaceutical Sciences, 2014, 103, 2072-2087.	1.6	80
28	Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. International Journal of Pharmaceutics, 2008, 357, 169-179.	2.6	79
29	Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. Toxicology and Applied Pharmacology, 2014, 274, 124-136.	1.3	79
30	The ontogeny of drug metabolizing enzymes and transporters in the rat. Reproductive Toxicology, 2008, 26, 220-230.	1.3	78
31	EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES. Drug Metabolism and Disposition, 2005, 33, 1004-1016.	1.7	77
32	Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. Journal of Pharmaceutical Sciences, 2011, 100, 5018-5030.	1.6	74
33	Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 75-90.	1.5	68
34	ASSESSMENT OF DRUG INTERACTIONS IN HEPATOBILIARY TRANSPORT USING RHODAMINE 123 IN SANDWICH-CULTURED RAT HEPATOCYTES. Drug Metabolism and Disposition, 2005, 33, 388-394.	1.7	67
35	Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. European Journal of Pharmaceutical Sciences, 2010, 39, 15-22.	1.9	67
36	In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities. International Journal of Pharmaceutics, 2015, 478, 665-681.	2.6	63

#	Article	IF	CITATIONS
37	Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 1-7.	2.0	62
38	Higher clearance of micafungin in neonates compared with adults: role of ageâ€dependent micafungin serum binding. Biopharmaceutics and Drug Disposition, 2011, 32, 222-232.	1.1	61
39	Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. American Journal of Transplantation, 2017, 17, 2372-2380.	2.6	60
40	Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species. Pharmacological Reviews, 2021, 73, 597-678.	7.1	60
41	Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. International Journal of Pharmaceutics, 1998, 166, 45-53.	2.6	58
42	Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. European Journal of Pharmaceutical Sciences, 2009, 38, 479-488.	1.9	58
43	Supersaturation in human gastric fluids. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 184-189.	2.0	57
44	In Vitro Investigation of the Hepatobiliary Disposition Mechanisms of the Antifungal Agent Micafungin in Humans and Rats. Drug Metabolism and Disposition, 2010, 38, 1848-1856.	1.7	55
45	Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of Hiv Protease Inhibitors. Journal of Pharmaceutical Sciences, 2011, 100, 3636-3654.	1.6	55
46	Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes. Toxicology in Vitro, 2016, 34, 179-186.	1.1	55
47	Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. European Journal of Pharmaceutical Sciences, 2011, 43, 297-307.	1.9	54
48	The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate. International Journal of Pharmaceutics, 2011, 414, 118-124.	2.6	52
49	Boosting of HIV Protease Inhibitors by Ritonavir in the Intestine: The Relative Role of Cytochrome P450 and P-Glycoprotein Inhibition Based on Caco-2 Monolayers versus In Situ Intestinal Perfusion in Mice. Drug Metabolism and Disposition, 2012, 40, 1473-1477.	1.7	52
50	Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically III Adult Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 6782-6789.	1.4	52
51	Human tissue-engineered skeletal muscle: a novel 3D in vitro model for drug disposition and toxicity after intramuscular injection. Scientific Reports, 2018, 8, 12206.	1.6	51
52	Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharmaceutical Research, 1997, 14, 492-496.	1.7	48
53	The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension. Journal of Controlled Release, 2016, 230, 95-108.	4.8	43
54	Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology. International Journal of Pharmaceutics, 2013, 452, 8-13.	2.6	42

#	Article	IF	CITATIONS
55	Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. International Journal of Pharmaceutics, 2015, 478, 736-744.	2.6	42
56	Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. European Journal of Pharmaceutical Sciences, 2013, 49, 27-32.	1.9	41
57	Human and simulated intestinal fluids as solvent systems to explore food effects on intestinal solubility and permeability. European Journal of Pharmaceutical Sciences, 2014, 63, 178-186.	1.9	41
58	Confocal Imaging with a Fluorescent Bile Acid Analogue Closely Mimicking Hepatic Taurocholate Disposition. Journal of Pharmaceutical Sciences, 2014, 103, 1872-1881.	1.6	41
59	Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: Role of glycine conjugates. Toxicology in Vitro, 2014, 28, 218-230.	1.1	39
60	Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. Clinical Pharmacokinetics, 2020, 59, 97-110.	1.6	38
61	Hydration Changes Implicated in the Remarkable Temperature-Dependent Membrane Permeation of Cyclosporin A. Biochemistry, 2000, 39, 7621-7630.	1.2	37
62	INTESTINAL PERFUSION WITH MESENTERIC BLOOD SAMPLING IN WILD-TYPE AND KNOCKOUT MICE. Drug Metabolism and Disposition, 2009, 37, 1334-1337.	1.7	36
63	In Situ Intestinal Perfusion in Knockout Mice Demonstrates Inhibition of Intestinal P-Glycoprotein by Ritonavir Causing Increased Darunavir Absorption. Drug Metabolism and Disposition, 2010, 38, 1407-1410.	1.7	36
64	The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. Journal of Pharmaceutical Sciences, 2016, 105, 2974-2981.	1.6	36
65	Drug-induced Cholestasis: Mechanisms, Models, and Markers. Current Drug Metabolism, 2018, 19, 808-818.	0.7	36
66	Preventing release in the acidic environment of the stomach via occlusion in ordered mesoporous silica enhances the absorption of poorly soluble weakly acidic drugs. Journal of Pharmaceutical Sciences, 2011, 100, 4864-4876.	1.6	35
67	Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients. Therapeutic Drug Monitoring, 2017, 39, 77-82.	1.0	35
68	Integration of Placental Transfer in a Fetal–Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus. Clinical Pharmacokinetics, 2020, 59, 911-925.	1.6	35
69	In Vitro, Ex Vivo, and In Situ Intestinal Absorption Characteristics of the Antiviral Ester Prodrug Adefovir Dipivoxil. Journal of Pharmaceutical Sciences, 2000, 89, 1054-1062.	1.6	34
70	Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF. European Journal of Pharmaceutical Sciences, 2015, 67, 126-135.	1.9	34
71	Integration and validation of the ex vivo human placenta perfusion model. Journal of Pharmacological and Toxicological Methods, 2017, 88, 25-31.	0.3	34
72	Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Archives of Toxicology, 2018, 92, 1939-1952.	1.9	34

#	Article	IF	CITATIONS
73	Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area. Pediatric Infectious Disease Journal, 2016, 35, 183-188.	1.1	33
74	Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat. Toxicologic Pathology, 2016, 44, 189-210.	0.9	33
75	Protein-Binding Characteristics of Voriconazole Determined by High-Throughput Equilibrium Dialysis. Journal of Pharmaceutical Sciences, 2014, 103, 2565-2570.	1.6	32
76	Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation. AAPS Journal, 2015, 17, 1376-1387.	2.2	32
77	Cellular Accumulation of Cholyl-Glycylamido-Fluorescein in Sandwich-Cultured Rat Hepatocytes: Kinetic Characterization, Transport Mechanisms, and Effect of Human Immunodeficiency Virus Protease Inhibitors. Drug Metabolism and Disposition, 2008, 36, 1315-1321.	1.7	31
78	Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwichâ€cultured rat and human hepatocytes. Biopharmaceutics and Drug Disposition, 2010, 31, 178-188.	1.1	31
79	PXR/CYP3A4-Humanized Mice for Studying Drug–Drug Interactions Involving Intestinal P-Glycoprotein. Molecular Pharmaceutics, 2013, 10, 1056-1062.	2.3	31
80	In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism. , 2008, , 182-215.		30
81	Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metabolism and Disposition, 2000, 28, 1394-6.	1.7	30
82	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Archives of Toxicology, 2020, 94, 1151-1172.	1.9	28
83	Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. International Journal of Pharmaceutics, 1999, 186, 127-136.	2.6	27
84	Antenatal sildenafil administration to prevent pulmonary hypertension in congenital diaphragmatic hernia (SToP-PH): study protocol for a phase I/IIb placenta transfer and safety study. Trials, 2018, 19, 524.	0.7	27
85	Solubility Profiling of HIV Protease Inhibitors in Human Intestinal Fluids. Journal of Pharmaceutical Sciences, 2013, 102, 3800-3807.	1.6	26
86	A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates. Frontiers in Pharmacology, 2020, 11, 587.	1.6	26
87	Comparison of the Complexation between Methylprednisolone and Different Cyclodextrins in Solution by 1H-NMR and Molecular Modeling Studies. Journal of Pharmaceutical Sciences, 2010, 99, 3863-3873.	1.6	25
88	Intestinal behavior of the ester prodrug tenofovir DF in humans. International Journal of Pharmaceutics, 2015, 485, 131-137.	2.6	25
89	Mechanisms and in vitro models of drug-induced cholestasis. Archives of Toxicology, 2019, 93, 1169-1186.	1.9	25
90	Comparative performance of oral midazolam clearance and plasma 4βâ€hydroxycholesterol to explain interindividual variability in tacrolimus clearance. British Journal of Clinical Pharmacology, 2016, 82, 1539-1549.	1.1	24

#	Article	IF	CITATIONS
91	Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharmaceutical Research, 1999, 16, 1035-1040.	1.7	23
92	Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. Pharmaceutical Research, 1998, 15, 1168-1173.	1.7	22
93	Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis. European Journal of Clinical Pharmacology, 2011, 67, 753-755.	0.8	22
94	Sildenafil crosses the placenta at therapeutic levels in aÂdually perfused human cotyledon model. American Journal of Obstetrics and Gynecology, 2018, 219, 619.e1-619.e10.	0.7	22
95	Transplacental transport of paracetamol and its phase II metabolites using the ex vivo placenta perfusion model. Toxicology and Applied Pharmacology, 2019, 370, 14-23.	1.3	22
96	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. European Journal of Clinical Pharmacology, 2016, 72, 953-963.	0.8	21
97	Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial. International Journal of Antimicrobial Agents, 2018, 51, 562-570.	1.1	21
98	Connexin and Pannexin (Hemi)Channels: Emerging Targets in the Treatment of Liver Disease. Hepatology, 2019, 69, 1317-1323.	3.6	21
99	Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. British Journal of Clinical Pharmacology, 2022, 88, 4965-4984.	1.1	21
100	Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture. Journal of Pharmacological and Toxicological Methods, 2015, 73, 63-71.	0.3	20
101	SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Therapeutic Drug Monitoring, 2016, 38, 487-492.	1.0	20
102	Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs. Pharmaceutics, 2020, 12, 685.	2.0	20
103	Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data. Pharmaceutical Research, 2015, 32, 260-274.	1.7	19
104	Metabolism of the synthetic cannabinoids AMB-CHMICA and 5C-AKB48 in pooled human hepatocytes and rat hepatocytes analyzed by UHPLC-(IMS)-HR-MS E. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 189-197.	1.2	19
105	A comprehensive review on non-clinical methods to study transfer of medication into breast milk – A contribution from the ConcePTION project. Biomedicine and Pharmacotherapy, 2021, 136, 111038.	2.5	19
106	Species-Specific Interaction of HIV Protease Inhibitors With Accumulation of Cholyl-Glycylamido-Fluorescein (CGamF) in Sandwich-Cultured Hepatocytes. Journal of Pharmaceutical Sciences, 2010, 99, 2886-2898.	1.6	18
107	In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin. International Journal of Pharmaceutics, 2016, 510, 296-303.	2.6	18
108	On the Role of Illness Duration and Nutrient Restriction in Cholestatic Alterations that Occur During Critical Illness. Shock, 2018, 50, 187-198.	1.0	18

#	Article	IF	CITATIONS
109	Primary Hepatocytes in Sandwich Culture. Methods in Molecular Biology, 2015, 1250, 175-188.	0.4	18
110	Validation of a differential <i>in situ</i> perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling. Biopharmaceutics and Drug Disposition, 2010, 31, 278-285.	1.1	17
111	Age-Dependent Activity of the Uptake Transporters Ntcp and Oatp1b2 in Male Rat Hepatocytes: From Birth Till Adulthood . Drug Metabolism and Disposition, 2015, 43, 1-8.	1.7	17
112	Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake. Journal of Pharmaceutical Sciences, 2016, 105, 854-863.	1.6	17
113	Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers. Drug Metabolism and Disposition, 2018, 46, 1507-1513.	1.7	17
114	Current insights in the complexities underlying drug-induced cholestasis. Critical Reviews in Toxicology, 2019, 49, 520-548.	1.9	17
115	Non-clinical Models to Determine Drug Passage into Human Breast Milk. Current Pharmaceutical Design, 2019, 25, 534-548.	0.9	17
116	The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development. Pharmaceutics, 2021, 13, 44.	2.0	17
117	Multimodal non-linear optical imaging for the investigation of drug nano-/microcrystal–cell interactions. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 338-348.	2.0	16
118	Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype. Pharmacogenomics Journal, 2017, 17, 556-562.	0.9	16
119	Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. Clinical Pharmacokinetics, 2015, 54, 1151-1160.	1.6	15
120	Metabolism and Excretion of RWJ-333369 [1,2-Ethanediol, 1-(2-Chlorophenyl)-, 2-carbamate, (S)-] in Mice, Rats, Rabbits, and Dogs. Drug Metabolism and Disposition, 2007, 35, 566-575.	1.7	14
121	MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study. Drug Metabolism and Disposition, 2018, 46, 697-703.	1.7	14
122	Non-canonical roles of connexins. Progress in Biophysics and Molecular Biology, 2020, 153, 35-41.	1.4	14
123	Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis. Microorganisms, 2021, 9, 1310.	1.6	14
124	Pretransplant 4βâ€hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. British Journal of Clinical Pharmacology, 2017, 83, 2406-2415.	1.1	13
125	Primary hepatocytes and their cultures for the testing of drug-induced liver injury. Advances in Pharmacology, 2019, 85, 1-30.	1.2	13
126	Quantitative determination of colistin A/B and colistin methanesulfonate in biological samples using hydrophilic interaction chromatography tandem mass spectrometry. Drug Testing and Analysis, 2020, 12, 1183-1195.	1.6	13

#	Article	IF	CITATIONS
127	Cell Imaging Counting as a Novel Ex Vivo Approach for Investigating Drug-Induced Hepatotoxicity in Zebrafish Larvae. International Journal of Molecular Sciences, 2017, 18, 356.	1.8	12
128	Meropenem Target Attainment and Population Pharmacokinetics in Critically III Septic Patients with Preserved or Increased Renal Function. Infection and Drug Resistance, 2022, Volume 15, 53-62.	1.1	12
129	Site dependent intestinal absorption of darunavir and its interaction with ketoconazole. European Journal of Pharmaceutical Sciences, 2013, 49, 51-56.	1.9	11
130	Pharmacokinetic Profile of Voriconazole in a Critically Ill Patient on Therapeutic Plasma Exchange. Therapeutic Drug Monitoring, 2013, 35, 141-143.	1.0	11
131	Biomarkers of cholestasis. Biomarkers in Medicine, 2021, 15, 437-454.	0.6	11
132	Spatiotemporal imaging and pharmacokinetics of fluorescent compounds in zebrafish eleuthero-embryos after different routes of administration. Scientific Reports, 2021, 11, 12229.	1.6	11
133	Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 171-181.	1.2	11
134	Comparison of the disposition of ester prodrugs of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 monolayers. Pharmaceutical Research, 1998, 15, 239-245.	1.7	10
135	Verapamil hepatic clearance in four preclinical rat models: towards activityâ€based scaling. Biopharmaceutics and Drug Disposition, 2015, 36, 462-480.	1.1	10
136	Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 22-29.	2.0	10
137	Lipophilic nalmefene prodrugs to achieve a one-month sustained release. Journal of Controlled Release, 2016, 232, 196-202.	4.8	10
138	Fexofenadine, a Putative <i>In Vivo</i> Pâ€glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. Clinical Pharmacology and Therapeutics, 2017, 102, 989-996.	2.3	10
139	Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine. Pharmaceutical Research, 2017, 34, 2336-2348.	1.7	10
140	Stability of Therapeutic Albumin Solutions Used for Molecular Adsorbent Recirculating Systemâ€Based Liver Dialysis. Artificial Organs, 2012, 36, 29-41.	1.0	9
141	Biopharmaceutical profiling of a pyrido[4,3-d] pyrimidine compound library. International Journal of Pharmaceutics, 2013, 455, 19-30.	2.6	9
142	Metabolism of the synthetic cannabinoid 5F-PY-PICA by human and rat hepatocytes and identification of biliary analytical targets by directional efflux in sandwich-cultured rat hepatocytes using UHPLC-HR-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 296-307.	1.4	9
143	Safety Assessment of Compounds after In Vitro Metabolic Conversion Using Zebrafish Eleuthero Embryos. International Journal of Molecular Sciences, 2019, 20, 1712.	1.8	9
144	Cholestasis Differentially Affects Liver Connexins. International Journal of Molecular Sciences, 2020, 21, 6534.	1.8	9

#	Article	IF	CITATIONS
145	Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically III Patients with Pneumonia: An Observational Cohort Study. Antibiotics, 2021, 10, 557.	1.5	9
146	A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication. Therapeutic Drug Monitoring, 2021, 43, 512-518.	1.0	9
147	Unbound Ritonavir Concentrations in Rat and Human Hepatocytes. Journal of Pharmaceutical Sciences, 2015, 104, 2378-2387.	1.6	8
148	Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2. Pharmacology Research and Perspectives, 2019, 7, e00504.	1.1	8
149	Meropenem Stability in Human Plasma at â^20 °C: Detailed Assessment of Degradation. Antibiotics, 2021, 10, 449.	1.5	8
150	Serum Creatinine Patterns in Neonates Treated with Therapeutic Hypothermia for Neonatal Encephalopathy. Neonatology, 2022, 119, 686-694.	0.9	8
151	Drug Transport in the Liver. , 0, , 359-410.		7
152	Comparison between 2-hydroxypropyl-β-cyclodextrin and 2-hydroxypropyl-γ-cyclodextrin for inclusion complex formation with danazol. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2011, 71, 137-147.	1.6	7
153	Ordered Mesoporous Silica for the Delivery of Poorly Soluble Drugs. , 2011, , 203-219.		6
154	Extra collagen overlay prolongs the differentiated phenotype in sandwich-cultured rat hepatocytes. Journal of Pharmacological and Toxicological Methods, 2018, 90, 31-38.	0.3	6
155	Drug-induced cholestasis assay in primary hepatocytes. MethodsX, 2020, 7, 101080.	0.7	6
156	Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance. Clinical Pharmacokinetics, 2021, 60, 897-906.	1.6	6
157	Pharmacokinetics in Zebrafish Embryos (ZFE) Following Immersion and Intrayolk Administration: A Fluorescence-Based Analysis. Pharmaceuticals, 2021, 14, 576.	1.7	6
158	Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2022, 77, 2479-2488.	1.3	6
159	In vivo evaluation of different formulation strategies for sustained release injectables of a poorly soluble HIV protease inhibitor. Journal of Controlled Release, 2015, 199, 1-9.	4.8	5
160	Hepatic Clearance Prediction of Nine Human Immunodeficiency Virus Protease Inhibitors in Rat. Journal of Pharmaceutical Sciences, 2016, 105, 846-853.	1.6	5
161	Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes. Drug Metabolism and Disposition, 2016, 44, 389-397.	1.7	5
162	Biomarkers of propofol metabolism in neonates: the quest beyond ontogeny. Biomarkers in Medicine, 2017, 11, 933-936.	0.6	5

#	Article	IF	CITATIONS
163	Effect of Cryopreservation on Enzyme and Transporter Activities in Suspended and Sandwich Cultured Rat Hepatocytes. AAPS Journal, 2018, 20, 33.	2.2	5
164	Creatinine Trends and Patterns in Neonates Undergoing Whole Body Hypothermia: A Systematic Review. Children, 2021, 8, 475.	0.6	5
165	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. Antibiotics, 2021, 10, 1112.	1.5	5
166	Effect of Age on The Hepatocellularity Number for Wistar rats. Drug Metabolism and Disposition, 2016, 44, 944-947.	1.7	4
167	Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro–In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 537-543.	0.6	4
168	Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype. Pharmaceutical Research, 2017, 34, 1309-1319.	1.7	4
169	In vivo <scp>CYP</scp> 3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 50-55.	1.2	4
170	Population pharmacokinetics of propofol in neonates and infants: Gestational and postnatal age to determine clearance maturation. British Journal of Clinical Pharmacology, 2021, 87, 2089-2097.	1.1	4
171	Letter to the Editor regarding: Ceftriaxone exposure in patients undergoing extracorporeal membrane oxygenation. International Journal of Antimicrobial Agents, 2021, 57, 106326.	1.1	4
172	Pharmacokinetics and pharmacodynamics of sildenafil in fetal lambs on extracorporeal support. Biomedicine and Pharmacotherapy, 2021, 143, 112161.	2.5	4
173	Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates. Expert Opinion on Drug Metabolism and Toxicology, 0, , 1-12.	1.5	4
174	High Speed HPLC Determination of <i>Bis</i> (Pivaloyloxymethyl)-PMEA and Its Degradation Products, Mono(POM)-PMEA and PMEA. Journal of Liquid Chromatography and Related Technologies, 1996, 19, 2271-2283.	0.5	3
175	Hepatobiliary and intestinal elimination of darunavir in an integrated preclinical rat model. Xenobiotica, 2014, 44, 489-497.	0.5	3
176	Response to: â€~Bodyweightâ€adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. British Journal of Clinical Pharmacology, 2017, 83, 1353-1356.	1.1	3
177	LC-MS/MS Analysis of Bile Acids in In Vitro Samples. Methods in Molecular Biology, 2019, 1981, 15-23.	0.4	3
178	Detection of Drug-Induced Cholestasis Potential in Sandwich-Cultured Human Hepatocytes. Methods in Molecular Biology, 2019, 1981, 335-350.	0.4	3
179	A sensitive liquid chromatography method for analysis of propofol in small volumes of neonatal blood. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 128-133.	0.7	3
180	Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 653-663.	0.6	3

#	Article	IF	CITATIONS
181	Determination of tacrolimus, three mono-demethylated metabolites and a M1 tautomer in human whole blood by liquid chromatography – tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114296.	1.4	3
182	QTc Intervals Are Prolonged in Late Preterm and Term Neonates during Therapeutic Hypothermia but Normalize Afterwards. Children, 2021, 8, 1153.	0.6	3
183	Synthesis and Early ADME Evaluation of a Novel Scaffold, Tetrahydro-6H-pyrido[3,2-b]azepin-6-one. Synlett, 2014, 25, 1443-1447.	1.0	2
184	In vitro disposition profiling of heterocyclic compounds. International Journal of Pharmaceutics, 2015, 491, 78-90.	2.6	2
185	Vesicle- and Hepatocyte-Based Assays for Identification of Drug Candidates Inhibiting BSEP Function. Methods in Molecular Biology, 2019, 1981, 55-73.	0.4	2
186	Development of a Pig Mammary Epithelial Cell Culture Model as a Non-Clinical Tool for Studying Epithelial Barrier—A Contribution from the IMI-ConcePTION Project. Animals, 2021, 11, 2012.	1.0	2
187	Bosentan alters endo- and exogenous bile salt disposition in sandwich-cultured human hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, JPET-AR-2021-000695.	1.3	2
188	Predicting modelâ€informed precision dosing: A testâ€case in tacrolimus dose adaptation for kidney transplant recipients. CPT: Pharmacometrics and Systems Pharmacology, 2022, , .	1.3	2
189	Identification of novel inhibitors of rat Mrp3. European Journal of Pharmaceutical Sciences, 2021, 162, 105813.	1.9	1
190	Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels. International Journal of Molecular Sciences, 2022, 23, 5018.	1.8	1
191	Insights into mechanisms underlying inter-individual susceptibility to Drug-Induced-Liver-Injury (DILI) from data on in vitro exposure, transcriptomics and functionality of cryopreserved human primary hepatocytes: The example of chlorpromazine. Toxicology Letters, 2013, 221, S151.	0.4	0
192	Glycine Formation Drives Bile Acid Toxicity in Sandwichâ€Cultured Human Hepatocyes. FASEB Journal, 2018, 32, lb647.	0.2	0
193	Dynamic Culturing of Rat Hepatocytes in Sandwich onfiguration Enhances and Maintains Formation of Biliary Networks. FASEB Journal, 2018, 32, lb653.	0.2	0